Advertisement

Management of acromegaly: Is there a role for primary medical therapy?

  • Zachary M. BushEmail author
  • Mary Lee Vance
Article

Abstract

Acromegaly is a chronic, debilitating disease caused by chronic growth hormone (GH) hypersecretion which results in chronic medical comorbidities, poor quality of life and high mortality rates. Successful treatment can improve clinical signs and symptoms and normalize mortality rates. Over 95% of acromegaly is caused by a somatotroph adenoma of the pituitary, and the first-line treatment is generally transsphenoidal surgery, which can be curative in 50–60% of patients. Nonetheless, high rates of persistent acromegaly following surgery and the limited efficacy of radiation therapy necessitate chronic medical treatment for many patients. Somatostatin analogues have become the preferred first-line medical therapy for many practitioners, as they achieve better biochemical and direct tumor control than the dopamine agonists, and long-acting preparations make once monthly administration possible. Cabergoline, a dopamine agonist, offers a lower-cost option and may be effective in patients with a pituitary tumor that co-secretes GH and prolactin. Pegvisomant is a GH receptor antagonist that produces exceptional biochemical response rates but lacks any direct effects on the tumor, which may limit its effectiveness as life-long monotherapy. Combinations of these three drug classes have not been rigorously studied, and preliminary trials do not suggest improved clinical outcomes. While medical treatment options for acromegaly have significantly improved over the last 30 years, limitations remain, and a multi-specialty team approach is necessary for the effective long-term management of patients with acromegaly.

Keywords

Acromegaly Somatotroph adenoma Pituitary tumor Medical management 

References

  1. 1.
    Alexander L, Appleton D, Hall R, Ross W, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12(1):71–9.Google Scholar
  2. 2.
    Katznelson L. Drug Insight: primary medical therapy of acromegaly. Nat Clin Pract Endocrinol Metab 2006;2:109–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Colao A, Ferone D, Marzullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr Rev 2004;25(1):102–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Melmed S. Acromegaly. N Engl J Med 1990;322(14):941–1012.CrossRefGoogle Scholar
  5. 5.
    Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90(8):4465–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45(4):407–13.CrossRefGoogle Scholar
  7. 7.
    Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol 1988;28(5):515–24.Google Scholar
  8. 8.
    Grunstein R, Ho K, Sullivan C. Sleep apnea in acromegaly. Ann Int Med 1991;115(7):527–32.PubMedGoogle Scholar
  9. 9.
    Hoffstein V, Chan CK, Slutsky AS. Sleep apnea and systemic hypertension: A causal association review. Am J Med 1991;91(2):190–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Palomäki H, Partinen M, Erkinjuntti T, Kaste M. Snoring, sleep apnea syndrome, and stroke. Neurology 1992;42 7 Suppl 6:75–81.PubMedGoogle Scholar
  11. 11.
    Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80(12):3395–402.PubMedCrossRefGoogle Scholar
  12. 12.
    Soszynski P, Slowinska-Srzednicka J, Zgliczynski S. Plasma concentrations of atrial natriuretic hormone in acromegaly: relationship to hypertension. Acta Endocrinol (Copenh) 1991;125(3):268–72.Google Scholar
  13. 13.
    Van Loon GR. Abnormal plasma catecholamine responses in acromegalics. J Clin Endocrinol Metab 1979;48(5):784–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996;17(5):423–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Moller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 2003;13(2–3):55–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, degli Uberti EC. Diurnal Rhythm of Plasma Catecholamines in Acromegaly. J Clin Endocrinol Metab 1999;84(7):2458–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, Jorgensen JO, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001;281(6):E1326–332.PubMedGoogle Scholar
  18. 18.
    Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4(4):239–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Bates AS, Hoff WV, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. QJM 1993;86(5):293–9.PubMedGoogle Scholar
  20. 20.
    Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. 1993;16(3):181–7.Google Scholar
  21. 21.
    Swearingen B, Barker FG II, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83(10):3419–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83(8):2730–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Melmed S. Clinical perspective: acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86(7):2929–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol 2001;54(2):137–54.CrossRefGoogle Scholar
  25. 25.
    Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997;82(4):1047–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83(10):3411–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Bates A. Does treatment of acromegaly affect life expectancy. Metabolism 1995;44(11):1–5.CrossRefGoogle Scholar
  28. 28.
    Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88(10):4709–19.PubMedCrossRefGoogle Scholar
  30. 30.
    Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005;152(3):379–87.PubMedCrossRefGoogle Scholar
  31. 31.
    Kreutzer J, Vance ML, Lopes MBS, Laws ER Jr. Surgical management of GH-Secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86(9):4072–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Clayton. How many surgeons to operate on acromegalic patients. Clin Endocrinol 1999;50(5):557–9.CrossRefGoogle Scholar
  33. 33.
    Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21(3):669–92.PubMedGoogle Scholar
  34. 34.
    Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor i in patients with acromegaly. J Clin Endocrinol Metab 1997;82(10):3187–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85(7):2476–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000;85(5):2068–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Landolt A, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998;88(6):1002–8.PubMedGoogle Scholar
  38. 38.
    Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90(8):4483–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Ferjoux G, Bousquet C, Cordelier P, Bali NL, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000;94:205–10.PubMedCrossRefGoogle Scholar
  41. 41.
    Buscail L, Esteve J, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll A, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Nat Acad Sci USA 1995;92(5):1580–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Cordelier P, Esteve JP, Bousquet C, Delesque N, O’Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtypeásst5. Proc Nat Acad Sci USA 1997;94(17):9343–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002;659(4):200–6.CrossRefGoogle Scholar
  45. 45.
    Battershill P, Clissold S. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38(5):658–702.PubMedCrossRefGoogle Scholar
  46. 46.
    Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin(R) LAR(R): A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45 Supplement 1:67–71.PubMedCrossRefGoogle Scholar
  47. 47.
    Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 2004;61(2):209–15.CrossRefGoogle Scholar
  48. 48.
    Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707–16.PubMedCrossRefGoogle Scholar
  49. 49.
    Anthony L. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S216–8.PubMedGoogle Scholar
  50. 50.
    Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002;63(3):162–5.PubMedGoogle Scholar
  51. 51.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779–86.PubMedCrossRefGoogle Scholar
  52. 52.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as Primary Therapy for Acromegaly. J Clin Endocrinol Metab 1998;83(9):3034–40.PubMedCrossRefGoogle Scholar
  53. 53.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LARR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002;56(1):65–71.CrossRefGoogle Scholar
  54. 54.
    Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol 2003;58(4):471–81.CrossRefGoogle Scholar
  55. 55.
    Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exper Clin Endocrinol Diabetes 2005;3:139–44.CrossRefGoogle Scholar
  56. 56.
    Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99–104.PubMedCrossRefGoogle Scholar
  57. 57.
    van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150(4):489–95.PubMedCrossRefGoogle Scholar
  58. 58.
    Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45(7):836–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Melmed S. Acromegaly. N Engl J Med 2006;355(24):2558–73.PubMedCrossRefGoogle Scholar
  61. 61.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143(5):577–84.PubMedCrossRefGoogle Scholar
  62. 62.
    Livadas S, Hadjidakis J, Argyropoulou M, Stamatelatou M, Kelekis D, Raptis S. Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens) 2006 2007;5(1):57–63.Google Scholar
  63. 63.
    Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1987;16(3):529–1.PubMedGoogle Scholar
  64. 64.
    Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82(10):3308–14.PubMedCrossRefGoogle Scholar
  65. 65.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83(2):374–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, et al. Medical treatment of acromegaly with SMS 201–995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 1987;64(3):447–53.PubMedGoogle Scholar
  67. 67.
    Plockinger O, Quabbe H. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly. J Endocrinol Invest 1991;14(11):943–8.PubMedGoogle Scholar
  68. 68.
    Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974;38(5):910–2.PubMedGoogle Scholar
  69. 69.
    Thorner M, Chait A, Aitken M, Benker G, Bloom SR. Bromocriptine treatment of acromegaly. Br Med J 1975;1:299–303.PubMedGoogle Scholar
  70. 70.
    Sachdev Y, Gopal K, Garg VK. Bromocriptine therapy in acromegaly. A long-term review of 35 cases. Postgrad Med J 1981;57(666):210–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Jaffe C, Barkan A. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21(3):713–35.PubMedGoogle Scholar
  72. 72.
    Lindholm J, Riishede J, Vestergaard S, Hummer L, Faber O, Hagen C. No effect of bromocriptine in acromegaly: a controlled trial. N Engl J Med 1981;304(24):1450–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Nortier J, Croughs R, Thijssen J, Schwarz F. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests. Clin Endocrinol 1984;20 May (5):565–71.Google Scholar
  74. 74.
    Quabbe H. Treatment results in 235 patients with acromegaly. A report of the acromegaly study group. Acta Endocrinol (Copenh). 1981;240 Suppl:66.Google Scholar
  75. 75.
    Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology 2006;67(7):1225–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 1990;87(13):5061–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256(5064):1677–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.PubMedCrossRefGoogle Scholar
  79. 79.
    van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Feenstra J, de Herder WW, ten Have SMTH, van den Beld AW, Feelders RA, Janssen JAMJ, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet 2005;365(9471):1644–6.CrossRefGoogle Scholar
  81. 81.
    Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156(1):75–82.PubMedCrossRefGoogle Scholar
  82. 82.
    Neggers SJCM, van Aken MO, Janssen JAMJ, Feelders RA, de Herder WW, van der Lely A-J. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007 (in press).Google Scholar
  83. 83.
    van der Hoek J, de Herder WW, Feelders RA, van der Lely A-J, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89(2):638–45.PubMedCrossRefGoogle Scholar
  84. 84.
    Surya S, Barkan A. GH Receptor antagonist: mechanism of action and clinical utility. Rev Endoc Metab Disord 2005;6(1):5–13.CrossRefGoogle Scholar
  85. 85.
    Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 2004;16(2):175–86.PubMedCrossRefGoogle Scholar
  86. 86.
    Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005;26(3):131–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007;156 suppl_1:S23–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of Hetero-Oligomers with enhanced functional activity. Science 2000;288(5463):154–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Medicine, Division of Endocrinology and MetabolismUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations